Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement prod… Read more
Edwards Lifesciences Corp - Asset Resilience Ratio
Edwards Lifesciences Corp (EW) has an Asset Resilience Ratio of 28.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Edwards Lifesciences Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Edwards Lifesciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.69 Billion | 20.23% |
| Short-term Investments | $1.16 Billion | 8.71% |
| Total Liquid Assets | $3.84 Billion | 28.95% |
Asset Resilience Insights
- Very High Liquidity: Edwards Lifesciences Corp maintains exceptional liquid asset reserves at 28.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Edwards Lifesciences Corp Industry Peers by Asset Resilience Ratio
Compare Edwards Lifesciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Edwards Lifesciences Corp (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Edwards Lifesciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.45% | $3.98 Billion | $13.06 Billion | +12.89pp |
| 2023-12-31 | 17.56% | $1.64 Billion | $9.36 Billion | +2.91pp |
| 2022-12-31 | 14.66% | $1.22 Billion | $8.29 Billion | -2.60pp |
| 2021-12-31 | 17.25% | $1.47 Billion | $8.50 Billion | -2.13pp |
| 2020-12-31 | 19.38% | $1.40 Billion | $7.24 Billion | -4.00pp |
| 2019-12-31 | 23.38% | $1.52 Billion | $6.49 Billion | +5.41pp |
| 2018-12-31 | 17.97% | $956.50 Million | $5.32 Billion | -5.51pp |
| 2017-12-31 | 23.48% | $1.34 Billion | $5.70 Billion | -4.70pp |
| 2016-12-31 | 28.18% | $1.27 Billion | $4.51 Billion | +15.71pp |
| 2015-12-31 | 12.47% | $506.30 Million | $4.06 Billion | -9.80pp |
| 2014-12-31 | 22.27% | $785.00 Million | $3.52 Billion | +3.32pp |
| 2013-12-31 | 18.96% | $516.50 Million | $2.72 Billion | +9.48pp |
| 2012-12-31 | 9.48% | $210.50 Million | $2.22 Billion | -4.63pp |
| 2011-12-31 | 14.10% | $279.30 Million | $1.98 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $1.77 Billion | -- |
| 2008-12-31 | 0.58% | $8.10 Million | $1.40 Billion | -3.09pp |
| 2007-12-31 | 3.67% | $49.40 Million | $1.35 Billion | -- |